SG11201402611WA - Natural-killer/t-cell lymphoma (nktcl) susceptibility prediction, diagnosis and therapy - Google Patents

Natural-killer/t-cell lymphoma (nktcl) susceptibility prediction, diagnosis and therapy

Info

Publication number
SG11201402611WA
SG11201402611WA SG11201402611WA SG11201402611WA SG11201402611WA SG 11201402611W A SG11201402611W A SG 11201402611WA SG 11201402611W A SG11201402611W A SG 11201402611WA SG 11201402611W A SG11201402611W A SG 11201402611WA SG 11201402611W A SG11201402611W A SG 11201402611WA
Authority
SG
Singapore
Prior art keywords
nktcl
killer
diagnosis
therapy
natural
Prior art date
Application number
SG11201402611WA
Other languages
English (en)
Inventor
Bin Tean Teh
Soon Thye Lim
Original Assignee
Singapore Health Serv Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Singapore Health Serv Pte Ltd filed Critical Singapore Health Serv Pte Ltd
Priority to SG11201402611WA priority Critical patent/SG11201402611WA/en
Publication of SG11201402611WA publication Critical patent/SG11201402611WA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027New or modified breeds of vertebrates
    • A01K67/0275Genetically modified vertebrates, e.g. transgenic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/275Nitriles; Isonitriles
    • A61K31/277Nitriles; Isonitriles having a ring, e.g. verapamil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57426Specifically defined cancers leukemia
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/03Animal model, e.g. for test or diseases
    • A01K2267/0331Animal model for proliferative diseases
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/91Transferases (2.)
    • G01N2333/912Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/91Transferases (2.)
    • G01N2333/912Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205Phosphotransferases in general
    • G01N2333/9121Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G01N2333/91215Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases with a definite EC number (2.7.1.-)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/50Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Environmental Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
SG11201402611WA 2011-11-25 2012-11-26 Natural-killer/t-cell lymphoma (nktcl) susceptibility prediction, diagnosis and therapy SG11201402611WA (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
SG11201402611WA SG11201402611WA (en) 2011-11-25 2012-11-26 Natural-killer/t-cell lymphoma (nktcl) susceptibility prediction, diagnosis and therapy

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SG2011088002 2011-11-25
SG11201402611WA SG11201402611WA (en) 2011-11-25 2012-11-26 Natural-killer/t-cell lymphoma (nktcl) susceptibility prediction, diagnosis and therapy
PCT/SG2012/000444 WO2013077814A2 (en) 2011-11-25 2012-11-26 Natural-killer/t-cell lymphoma (nktcl) susceptibility prediction, diagnosis and therapy

Publications (1)

Publication Number Publication Date
SG11201402611WA true SG11201402611WA (en) 2014-06-27

Family

ID=54257023

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201402611WA SG11201402611WA (en) 2011-11-25 2012-11-26 Natural-killer/t-cell lymphoma (nktcl) susceptibility prediction, diagnosis and therapy
SG10201605729TA SG10201605729TA (en) 2011-11-25 2012-11-26 Natural-killer/t-cell lymphoma (nktcl) susceptibility prediction, diagnosis and therapy

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201605729TA SG10201605729TA (en) 2011-11-25 2012-11-26 Natural-killer/t-cell lymphoma (nktcl) susceptibility prediction, diagnosis and therapy

Country Status (6)

Country Link
US (2) US20150292022A1 (enrdf_load_stackoverflow)
EP (1) EP2782562B1 (enrdf_load_stackoverflow)
JP (1) JP2015505669A (enrdf_load_stackoverflow)
CN (1) CN104220051B (enrdf_load_stackoverflow)
SG (2) SG11201402611WA (enrdf_load_stackoverflow)
WO (1) WO2013077814A2 (enrdf_load_stackoverflow)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6416508B2 (ja) * 2014-06-05 2018-10-31 公益財団法人がん研究会 Nk/t細胞リンパ腫の検査方法
JP2020500940A (ja) * 2016-12-09 2020-01-16 オンキミューネ リミテッド 向上したnk細胞ベースの治療
EP3692174A4 (en) * 2017-10-06 2021-06-23 Singapore Health Services Pte Ltd LYMPHOMA TREATMENT METHODS
CN108841869B (zh) * 2018-05-31 2022-05-06 上海交通大学医学院附属瑞金医院 一种斑马鱼nk/tcl肿瘤模型的构建方法及其应用
NL2037024B1 (en) * 2024-02-14 2025-08-22 Stichting Het Nederlands Kanker Inst Antoni Van Leeuwenhoek Ziekenhuis Janus kinase (JAK) inhibitors for treating cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE369844T1 (de) * 2000-01-24 2007-09-15 Genzyme Corp Inhibitoren des jak/stat-weges und deren verwendung zur behandlung von allgemeiner primärer osteoarthritis
US20090285796A1 (en) * 2006-01-20 2009-11-19 Cell Signaling Technology, Inc. Mutant jak3 kinase in human leukemia

Also Published As

Publication number Publication date
EP2782562A2 (en) 2014-10-01
SG10201605729TA (en) 2016-08-30
US20150292022A1 (en) 2015-10-15
WO2013077814A2 (en) 2013-05-30
JP2015505669A (ja) 2015-02-26
EP2782562B1 (en) 2016-12-21
WO2013077814A3 (en) 2013-10-10
US10378062B2 (en) 2019-08-13
CN104220051A (zh) 2014-12-17
CN104220051B (zh) 2017-04-19
US20170029899A1 (en) 2017-02-02

Similar Documents

Publication Publication Date Title
IL222778A0 (en) Diabetes therapy
GB2487355B (en) Processing apparatus, trace unit and diagnostic apparatus
SG11201402113SA (en) Re-encryption system, re-encryption apparatus, and program
PT2621569T (pt) Dispositivo de tratamento
AP2014007420A0 (en) Integrated portable medical diagnostic system
EP2531153A4 (en) MEDICAL DEVICE
EP2377457A4 (en) MEDICAL DEVICE
GB201003817D0 (en) Medical device
EP2909342A4 (en) MONITORING OF LARGE B-CELL DIFFUSED LYMPHOMA FROM PERIPHERAL BLOOD SAMPLES
EP2586495A4 (en) BREATHING DEVICE, BREATHING PROGRAM AND PARTICLE BEAM THERAPY DEVICE
EP2652506A4 (en) USE OF ANTIBODIES AGAINST CXCL16 AND CXCR6 FOR TREATMENT OR FOR THE DETECTION OF CANCER
PL2512547T3 (pl) Urządzenie bilansujące, zewnętrzne medyczne urządzenie funkcyjne, urządzenie obróbkowe
EP2555036A4 (en) ENDOSCOPIC DEVICE AND CONNECTION UNIT FOR ENDOSCOPE DEVICE
ZA201205425B (en) Treatment with vb-201
GB201008541D0 (en) Diagnostic methods
EP2621497A4 (en) ASSOCIATION TREATMENT FOR ROSE ACNE
AP2013006855A0 (en) Medical device
GB2483509B (en) Data processing apparatus, trace unit and diagnostic apparatus
GB201007075D0 (en) Diagnostic reagents
SG10201601853XA (en) Pericyte progenitors from peripheral blood
GB2482171B (en) Catalyst treatment
GB201005122D0 (en) Medical device
SG10201605729TA (en) Natural-killer/t-cell lymphoma (nktcl) susceptibility prediction, diagnosis and therapy
PL2591858T3 (pl) Kaseta reakcyjna i urządzenie testowe
PT2630475T (pt) Método de diagnóstico e tratamento